Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Stephen H. Gillespie(University of St Andrews), Andrew Nunn(MRC Clinical Trials Unit at UCL)
Cited by 653
Related Papers
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
|The Lancet|2003|828
New strategies for clinical trials in patients with sepsis and septic shock
|Critical Care Medicine|2001|157
Perspective for Precision Medicine for Tuberculosis
|Frontiers in Immunology|2020|69
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
|The International Journal of Tuberculosis and Lung Disease|2021|63